Drug Safety

Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, the Netherlands, and the UK

Sieta T. de Vries, PhD1,2; Petra Denig, PhD1; Adriana Andrić, MD3,4; Marina Dimov Di Giusti, MD3,4; Alicia Ptaszynska-Neophytou5; Linda Härmalk, PhD6; Peter G.M. Mol, PhD1,2,7; on behalf of IMI Web-RADR work package 3b consortium and SCOPE Joint Action work package 4.

1 University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, The Netherlands
2 Web-RADR work package 3B
3 Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Croatia
4 SCOPE Joint Action work package 4
5 Medicines and Healthcare products Regulatory Agency, London, UK
6 Netherlands Pharmacovigilance Centre Lareb, ‘s-Hertogenbosch, The Netherlands
7 Dutch Medicines Evaluation Board, Utrecht, the Netherlands

Corresponding author:
P.G.M. Mol, PhD
E-mail: p.g.m.mol@umcg.nl
Phone: +31 (0)50-3617861
Fax +31 (0)50-3617889
### Electronic Supplementary Material Table 5.
Number (%) of patients selecting the different answer options for motives (not) to report adverse drug reactions and P-values for tests of differences across the countries

| Motives                                                                 | Total | Croatia (HR) | Netherlands (NL) | UK       | P-value       |
|------------------------------------------------------------------------|-------|---------------|------------------|----------|---------------|
| **A. In your opinion, what are the benefits of reporting side-effects directly to the national agency?**
I can offer my perspective by describing my own experience               | 213 (51) | 68 (50)       | 89 (49)         | 56 (57)  | 0.487         |
| I can contribute to the safety of medicines                            | 353 (85) | 115 (85)      | 144 (80)        | 94 (95)  | 0.004 (V=0.16) |
|                                                                      |       |               |                  |          | HR – NL: 0.297 |
|                                                                      |       |               |                  |          | NL – UK: 0.001 |
|                                                                      |       |               |                  |          | HR – UK: 0.012 |
| I can share my experience for the benefit of others                    | 329 (79) | 103 (76)      | 137 (76)        | 89 (90)  | 0.011 (V=0.15) |
|                                                                      |       |               |                  |          | HR – NL: 0.938 |
|                                                                      |       |               |                  |          | NL – UK: 0.005 |
|                                                                      |       |               |                  |          | HR – UK: 0.006 |
| I can report independently of healthcare professionals                  | 257 (62) | 91 (67)       | 107 (59)        | 59 (60)  | 0.344         |
| I can report side effects that I’m embarrassed to discuss with healthcare professionals | 98 (24) | 44 (32)       | 19 (11)         | 35 (35)  | <0.001 (V=0.27) |
|                                                                      |       |               |                  |          | HR – NL: <0.001 |
|                                                                      |       |               |                  |          | NL – UK: <0.001 |
|                                                                      |       |               |                  |          | HR – UK: 0.631 |
| **B. What are in your opinion the drawbacks of reporting side-effects directly to the national agency?**
I do not know how to report                                              | 146 (47) | 52 (48)       | 55 (43)         | 39 (52)  | 0.439         |
| I do not know what happens with my report after I report              | 197 (63) | 76 (70)       | 75 (59)         | 46 (61)  | 0.160         |
| Reporting is too complicated or time-consuming                        | 73 (23) | 27 (25)       | 16 (13)         | 30 (40)  | <0.001 (V=0.25) |
|                                                                      |       |               |                  |          | HR – NL: 0.013 |
|                                                                      |       |               |                  |          | NL – UK: <0.001 |
|                                                                      |       |               |                  |          | HR – UK: 0.031 |
| There is no direct benefit for me personally from reporting            | 52 (17) | 23 (21)       | 18 (14)         | 11 (15)  | 0.286         |
| I do not want to share my personal data                                | 38 (12) | 17 (16)       | 15 (12)         | 6 (8)    | 0.283         |
| I do not want to be contacted after I report                           | 15 (5) | 6 (6)         | 6 (5)           | 3 (4)    | 0.886         |

1 1 missing; 7 ‘none’; 2 112 ‘none’